- Home
- PIII vs ABVC Comparison
PIII vs ABVC Comparison
Compare PIII & ABVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ABVC
- Stock Information
- Founded
- PIII 2015
- ABVC 2015
- Country
- PIII United States
- ABVC United States
- Employees
- PIII N/A
- ABVC N/A
- Industry
- PIII Medical/Nursing Services
- ABVC Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ABVC Health Care
- Exchange
- PIII Nasdaq
- ABVC Nasdaq
- Market Cap
- PIII 21.4M
- ABVC 22.1M
- IPO Year
- PIII N/A
- ABVC N/A
- Fundamental
- Price
- PIII $6.37
- ABVC $2.24
- Analyst Decision
- PIII Buy
- ABVC
- Analyst Count
- PIII 2
- ABVC 0
- Target Price
- PIII $16.25
- ABVC N/A
- AVG Volume (30 Days)
- PIII 5.1K
- ABVC 389.6K
- Earning Date
- PIII 08-06-2025
- ABVC 08-13-2025
- Dividend Yield
- PIII N/A
- ABVC N/A
- EPS Growth
- PIII N/A
- ABVC N/A
- EPS
- PIII N/A
- ABVC N/A
- Revenue
- PIII $1,485,192,000.00
- ABVC $508,383.00
- Revenue This Year
- PIII N/A
- ABVC $735.18
- Revenue Next Year
- PIII $6.01
- ABVC N/A
- P/E Ratio
- PIII N/A
- ABVC N/A
- Revenue Growth
- PIII 9.79
- ABVC 1904.43
- 52 Week Low
- PIII $6.00
- ABVC $0.40
- 52 Week High
- PIII $32.54
- ABVC $2.70
- Technical
- Relative Strength Index (RSI)
- PIII 33.55
- ABVC 70.75
- Support Level
- PIII $6.00
- ABVC $1.84
- Resistance Level
- PIII $6.35
- ABVC $2.29
- Average True Range (ATR)
- PIII 0.22
- ABVC 0.16
- MACD
- PIII 0.03
- ABVC 0.03
- Stochastic Oscillator
- PIII 21.62
- ABVC 87.65
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.